Effects of sevoflurane postconditioning on cell death, inflammation and TLR expression in human endothelial cells exposed to LPS by Rodríguez González, Raquel et al.
Rodríguez-González et al. Journal of Translational Medicine 2013, 11:87
http://www.translational-medicine.com/content/11/1/87RESEARCH Open AccessEffects of sevoflurane postconditioning on cell
death, inflammation and TLR expression in
human endothelial cells exposed to LPS
Raquel Rodríguez-González1,2,3, Aurora Baluja1, Sonia Veiras Del Río1, Alfonso Rodríguez1, Jaime Rodríguez1,
Manuel Taboada1, David Brea4,5 and Julián Álvarez1*Abstract
Background: Sevoflurane is an anesthetic agent which also participates in protective mechanisms in sepsis, likely
due to anti-inflammatory properties. A key tissue in sepsis is the endothelium, which expresses TLR2 and TLR4
receptors, known regulators of inflammatory mechanisms and potential therapeutic targets for this pathology. In
this context, we explored the effect of sevoflurane postconditioning in an in vitro sepsis model.
Methods: Primary cultures of human umbilical vein endothelial cells were used for two different experiments. In
the first set, cultures were placed in an airtight incubation chamber and exposed to different concentrations of
sevoflurane (0,1,3 or 7% vol,) for 1 hour. In the second set, lipopolysaccharide from Escherichia coli 0111:B4 (1 μg/
mL) was added to culture medium for 3 hours and cells were subsequently exposed to sevoflurane (0,1,3 or 7%
vol,) for 1 hour as explained before. In both cases, cell viability was measured by MTT and Trypan blue assays, TLR2
and TLR4 expression were analyzed by flow cytometry, and TNFα and IL-6 levels were quantified in cell culture
media by an immunoassay immediately after exposure, at 6 and 24 hours.
Results: Exposure to 3% sevoflurane decreased TLR2 at 24 hours and TLR4 at 6 and 24 hours (both p<0.05),
whereas exposure to 7% decreased TLR4 expression at 6 hours (p<0.05). Both 3 and 7% sevoflurane decreased
TNF-α and IL-6 levels at 24 hours (both p<0.05). In LPS-stimulated cultures, exposure to 3% sevoflurane was
cytoprotective at 6 and 24 hours (p<0.05) compared with control, and decreased TLR2 and TLR4 expression at 24
hours (p<0.05); whereas 7% decreased TLR4 expression at 24 hours (p<0.05). Both 3% and 7% sevoflurane
decreased TNF-α and IL-6 levels at 24 hours (both p<0.05).
Conclusions: Postconditioning with the halogenated anesthetic agent sevoflurane after LPS stimulation shows a
cytoprotective effect in an in vitro model, decreasing cell death and reducing TLR2 and TLR4 expression as well as
levels of the inflammatory mediators TNF-α and IL-6 in human endothelial cells.
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Sepsis remains a major clinical problem due to high
morbidity and mortality with limited therapeutic op-
tions, being the leading cause of death in non-coronary
intensive care units and an important burden for
healthcare resources. A crucial tissue involved in sepsis* Correspondence: julian.alvarez.escudero@sergas.es
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hemodynamics, immunity and coagulation pathways, the
three main cornerstones of septic response [1].
Sevoflurane is a highly fluorinated methyl-isopropyl
ether widely used for induction and maintenance of gen-
eral anesthesia. In addition to its anesthetic properties, it
has also shown to be involved in protective mechanisms
in conditions of hypoxia or endotoxemia, mostly studied
in neuronal and myocardial tissues [2-4]. A study by
Kidani et al. examined the effects of sevoflurane pretreat-
ment on mortality and inflammation during endotoxin-Med Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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pretreatment significantly improved systolic blood pres-
sure, acid–base balance and reduced mortality rates and
plasma levels of TNF-α and IL-6, thus showing an attenu-
ation of the inflammatory response [5].
In addition to preconditioning, it has been demon-
strated that sevoflurane induces a postconditioning ef-
fect after exposure to hypoxia or lipopolysaccharide
(LPS). In this regard, it has been demonstrated that
sevoflurane postconditioning decreases blood and brain
oxidative injury and enhances immunity indexes in rats
subjected to cerebral ischemia-reperfusion [6]. Import-
antly, data from Yue et al. analyzing sevoflurane post-
conditioning in an in vitro model of acute lung injury
show that it significantly reduced inflammatory media-
tors, chemotaxis and neutrophil adherence [7]. There-
fore, evidence from experimental data support the idea
of sevoflurane postconditioning as an organ-protective
strategy.
Bacterial infection initiates a series of responses that
contribute to endothelial dysfunction, resulting in fluid
leakage, platelet adherence and the release of adhesion
molecules and inflammatory mediators, among others.
Consequently, endothelial cells are key players in sepsis,
expressing toll-like receptor (TLR) 4 and TLR2, essential
components of the innate immune system and pathogen
recognition mechanisms. TLR-mediated signaling cas-
cade triggered by bacterial ligands result in the activa-
tion of NF-κB, leading to the transcription of a range of
important pro-inflammatory cytokine and chemokine
genes, such as TNFα, IL-1, IL-6, IL-12 and IL-8 [8-11],
playing an important role in endothelial inflammation.
Importantly, TLRs are dynamically modulated across the
stages of sepsis, and experimental data indicate that, by
dampening TLR-induced inflammatory pathways, it is
possible to interfere with the progression of sepsis [12,13].
Due to demonstrated anti-inflammatory effects of
sevoflurane preconditioning in sepsis, we aimed to in-
vestigate the possible effect of sevoflurane postcon-
ditioning in an in vitro model of endotoxaemia using
LPS-exposed human endothelial cells, a highly dynamic
tissue responsive to exposure to this anesthetic agent
[14], focusing on the interaction between sevoflurane




Human endothelial cells (HUVECs) were kindly pro-
vided by Dr. E. Álvarez (Instituto de Investigación
Sanitaria de Santiago de Compostela (IDIS), Spain). Cells
were isolated from freshly obtained human umbilical
cords donated under informed consent of the mothers
by following the method previously described [15]. Allprocedures were approved by the Ethics Committee for
Clinical Research in Galicia (Spain), according to the
World Medical Association Declaration of Helsinki.
After dissociation, HUVEC were cultured on 0.2%
gelatin-coated flasks (BD Biosciences, Madrid, Spain)
using endothelial cell growth medium (Promocell,
Heidelberg, Germany,) and grown to confluence in an
incubator at 37°C with a humidified atmosphere
containing 95% air/5% CO2. Cells were expanded by
trypsinization with 0.25% trypsin in PBS containing
0.025% EDTA (Sigma, Madrid, Spain). For the experi-
ments, cells were used between the second and fifth
passage and seeded at a density of 105cells per cm2
in multiwell plates (BD Biosciences, Madrid, Spain).
Medium was replaced every 3 days by fresh growth
medium and cells were allowed to reach confluence.
Sevoflurane exposure
To analyze the possible effect of sevoflurane on different
parameters, cultures were exposed to this anesthetic
agent mainly as previously described [16,17]. Endothelial
cells were exposed to three different concentrations of
sevoflurane (SevoraneW, Abbott Laboratories, Madrid,
Spain): 1, 3, or 7 vol.% by means of a vaporizer (Abbott)
for 1 hour. Cell cultures were placed in an airtight incu-
bation chamber (Billups-Rothenberg, Del Mar, CA) at a
constant temperature of 37°C and subsequently perfused
with air (21% O2, 5% CO2, 69% N2) containing 1, 3 or
7% sevoflurane. These doses have been selected in ac-
cordance to the clinical context, where sevoflurane doses
with anesthetic purposes range from 3% vol (induction)
to 5-8% vol (maintenance). After 12 minutes with a flow
rate of 4 L/min, sevoflurane concentrations in the cham-
ber remained stable. Gas concentrations of O2, CO2 and
sevoflurane were continuously monitored from the
output line by an anesthetic gas measurer module
(Capnomac Ultima, Datex Ohmeda, GE Healthcare,
Madrid, Spain), showing no sevoflurane loss in the cir-
cuit and remaining steady during the exposure time. For
each condition, control cells were superfused for the
same length of time with fresh air lacking sevoflurane.
Once exposure time was finished, cells were returned to
the incubator. In order to evaluate the temporal profile
of the analyzed molecules, samples of culture media and
cells were taken from both treated and control groups
immediately after finishing exposure (t=0), at 6 (t=6)
and 24 (t=24) hours after sevoflurane exposure. All ex-
periments were carried out three times in triplicate.
LPS treatment
In a different set of experiments, we aimed to analyze
sevoflurane-mediated cytoprotection after LPS treatment
in human endothelial cells. Pilot experiments testing in-
creasing doses of LPS were carried out in order to
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vates HUVEC in our cultures, resulting this to be 1 μg/
mL (data not shown). Therefore, 1 μg/mL LPS from
Escherichia coli 0111:B4 (Sigma) was added to the cul-
ture medium and cells were returned to the incubator.
Three hours after LPS stimulation, cell cultures were
exposed to sevoflurane for 1 hour as explained above
(1, 3 or 7% vol.% sevoflurane) in order to evaluate the
postconditioning effect of this anesthetic agent. Control
cells were treated with LPS but were not exposed to
sevoflurane. Samples of culture media and cells for ana-
lysis were taken from both treated and control groups
immediately after finishing sevoflurane exposure (t=0),
at 6 (t=6) and 24 (t=24) hours (see experimental proto-
col scheme in Additional file 1). Experiments were
conducted in triplicate.
MTT assay
Cell viability was analyzed by the colorimetric 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay carried out in cell samples collected just
after exposure (t=0), at 6 (t=6) and 24 (t=24) hours after,
using a commercial kit (Sigma) and a microplate reader
(Biotek) for spectrophotometric measurements.
Trypan blue exclusion assay
Cell death was also determined by Trypan blue dye ex-
clusion test. The assay is based on the fact that the dye
is negatively charged and does not interact with the cell
unless the membrane is damaged. At the mentioned
timepoints, cells from each group were detached by
trypsinization and subsequently collected by centrifuga-
tion. After resuspension in phosphate buffered saline,
equal volumes of cell suspension and 0.4% Trypan blue
(Invitrogen) were mixed and incubated for 10 min at
room temperature. The number of dead cells (blue
stained cells) was counted using a hemocytometer from
five random fields using a counting grid. Data are
expressed as percent of total cells/field ± SD.
Flow cytometry analysis of TLR2 and TLR 4
Expression of TLR2 and TLR4 on endothelial cells was
analyzed by flow cytometry at the mentioned timepoints.
APC-TLR2 antibody (BD Biosciences) and biotin-TLR4
antibody (BD Biosciences) together with streptavidin-PE
(BD Biosciences) were used to quantify TLR expression.
Samples were analyzed on a FACSAria flow cytometer
(BD Biosciences) [18]. Mean expression of TLR2 and
TLR4 on HUVEC was analyzed and expressed as AFU
(arbitrary fluorescence units).
Determination of TNF-.alpha; and IL-6
TNF-α and IL-6 were measured in the culture media of
all groups collected at the mentioned timepoints (t=0,t=6 and t=24) after sevoflurane exposure using
an immunoassay-based chemiluminescent automated
system (Immulite 1000, Siemens Healthcare, Madrid,
Spain). Inter- and intra assay coefficients of variation
were below 6% for both molecules.
Statistical analysis
Results are expressed as mean ± standard deviation (SD)
of the indicated number of experiments, and statistical
analysis was made using Student’s t test with SPSS 14.0
software. P values <0.05 were considered statistically
significant.
Results
Effects of sevoflurane exposure on endothelial cultures
Sevoflurane exposure did not induce cell death in our
cultures at any studied concentration or timepoint, as
revealed by both MTT and Trypan blue assays (see
Additional file 1), and no morphological alterations were
found (data not shown). However, flow cytometry ana-
lysis showed sevoflurane-induced changes in TLR2 and
TLR4 expression. Exposure to 3% sevoflurane lowered
TLR2 expression at all analyzed timepoints, being this
decrease statistically significant at 24 hours after expos-
ure compared to control (Figure 1a, p<0.05, n=9). With
respect to TLR4 expression, it was reduced by 3%
sevoflurane at 6 and 24 hours after exposure, while 7%
sevoflurane only showed a significant reduction at 6
hours compared to control (Figure 1b, all p<0.05, n=9).
Because TLR2 and TLR4 signalling cascades trigger in-
flammation, and given the relationship found between
sevoflurane and TLRs in the present study, we also mea-
sured levels of the inflammatory cytokines TNF-α and
IL-6 in our culture. These results show that exposure to
1% sevoflurane did not affect cytokine levels, whereas
sevoflurane at 3% and 7% significantly lowered both
TNF-α and IL-6 levels in culture media at 24 hours
(Figure 1c,d, both p<0.05, n=9).
Effect of sevoflurane exposure after LPS treatment on
endothelial cultures
In agreement with previous reports, LPS-treated
HUVEC showed a significant increase of TNF-α and IL-
6 levels in culture media both at 6 and 24 hours after
stimulation (see Additional file 1). The three tested
doses of sevoflurane after LPS administration showed
different cytoprotective effects on endothelial cultures,
as assessed by MTT or Trypan blue assays. Exposure to
1% sevoflurane did not induce a statistically significant
cytoprotective effect (Figure 2a,b, all p≥0.05, n=9). Ex-
posure to 3% sevoflurane after LPS lead to a statistically
significant cytoprotective effect at 6 and 24 hours com-
pared to control (Figure 2a,b p<0.05 and p<0.01 respect-
ively, n=9), while no significant effect was observed on
Figure 1 Effect of different concentrations of sevoflurane on HUVEC cultures at different timepoints. (a) Effect on TLR2 expression; (b)
effect on TLR4 expression; (c) levels of TNF-α (d) and IL-6. * p <0.05. Analysis was performed immediately after finishing sevoflurane exposure
(t=0), at 6 (t=6) and 24 (t=24) hours. AFU: Arbitrary fluorescence units.
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to TLR expression, exposure to 1% sevoflurane did not
change TLR2 or TLR4 levels in our cultures (Figure 3a,
b, all p≥0.05, n=9). By contrast, 3% sevoflurane signifi-
cantly decreased both TLR2 and TLR4 expression 24
hours after exposure compared to control (Figure 3a,b,
p<0.05 and p<0.01, respectively, n=9). Exposure to 7%
sevoflurane did not affect TLR2 expression (Figure 3a,
p≥0.05, n=9), but significantly decreased TLR4 levels at
24 hours (Figure 3b, p<0.05, n=9). Due to the known ef-
fect of LPS on cytokine release, we also determined
TNF-α and IL-6 levels in this study group. Exposure to
1% sevoflurane did not modify TNF-α or IL-6 levels
compared to control (Figure 3c,d, all p≥0.05, n=9).
However, 3% and 7% sevoflurane decreased TNF-α
(Figure 3c, both p<0.01, n=9) and IL-6 levels (Figure 3d,
both p<0.001, n=9) at 24 hours.
Discussion
The present study shows sevoflurane-induced changes
on the inflammatory response in human endothelial
cells. Importantly, sevoflurane postconditioning after
LPS administration shows a cytoprotective effect, a de-
crease of TLR2 and TLR4 expression as well as inflam-
matory mediators.
Sevoflurane has proven to reduce perioperative mor-
bidity and mortality [19,20], showing non-anesthetic
properties that involve cytoprotective effects related toits reduction of hypoxia or endotoxaemia-induced cell
damage due to mechanisms of pre-, intra- and post-
conditioning: an exposure to sevoflurane before, during or
after an insult. In the context of cardiac surgery [21,22]
and cerebral ischemia [23,24], hypoxia-related protective
mechanisms of preconditioning with volatile anesthetics
include hemodynamic mechanisms, up-regulation of
antiapoptotic factors, attenuation of excitotoxicity, or en-
hancement of endogenous reparative processes in the
brain [25,26]. Regarding endotoxaemia, available data
from experimental studies suggest that preconditioning
with halogenated anesthetics confers protection by inhib-
ition of the inflammatory response [5,27-29].
However, less is known about the postconditioning ef-
fect of sevoflurane, a more recent procedure that has
also shown to be an effective therapeutic strategy to re-
duce ischemia-induced damage in the brain and myocar-
dium [30,31] and to attenuate LPS-induced response in
experimental models in pulmonary cells [7,32]. These
studies have shown that beneficial effects of sevoflurane
on LPS-mediated damage involve a reduction of cell
death, an attenuation of the inflammatory response and
chemotactic mechanisms, as well as an increase in the
expression of molecules that protect cells against injury
such as the chaperone HSP-32.
TLR2 and TLR4 are potent initiators of the inflamma-
tory and immune response, triggering intracellular
signaling cascades that eventually result in the increase
Figure 2 Cytoprotective effect of sevoflurane postconditioning on HUVEC after LPS stimulation measured by MTT (a) and Trypan blue
(b) assays. * p<0.05, ** p<0.01. Analysis was performed immediately after sevoflurane exposure (t=0), at 6 (t=6) and 24 (t=24) hours.
LPS: Lipopolysaccharide.
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therefore playing an important role in sepsis pathogen-
esis [34,35]. Because exposure to sevoflurane has shown
to reduce inflammation, we aimed to investigate whether
this effect could be mediated by a sevoflurane-induced de-
crease of TLR expression in the endothelium, as a key tis-
sue involved in sepsis. In non-stimulated endothelial cells,
exposure to 3% or 7% sevoflurane decreased TLR4 levels.
TLR2 expression was lowered by 3% sevoflurane, but not
after exposure to a concentration of 7%, indicating that
this is not a dose-dependent effect. In these cultures, the
pro-inflammatory mediators TNF-α and IL-6 were also re-
duced, in agreement with previous studies that reported
an anti-inflammatory effect of this anesthetic agent [5,7].
Previous studies have reported an immunomodulatory ef-
fect of sevoflurane in mice [36,37], and pulmonary cells
[29], without detrimental effects on organ toxicity or cell
viability. However, this is, to the best of our knowledge,
the first report of a relationship between sevoflurane and
TLR expression in human cells.We subsequently investigated sevoflurane postcon-
ditioning effect on LPS-stimulated endothelial cells as an
in vitro model of endotoxaemia [38], and results indicate
that exposure to sevoflurane reduced cell toxicity, TLR2
and TLR4 expression as well as TNF-α and IL-6 levels.
This seems to be in accordance with studies by Steurer
et.al, reporting sevoflurane-mediated TNF-α decrease in
alveolar macrophages after LPS administration [39]. In
that study, a significant decrease in TNF-α levels was
found as soon as 2 hours after exposure, losing its sig-
nificance at 24 hours, whereas in our experiments this
was the time of maximum attenuation. We think that
the different cell type used as well as the exposure
length, notably shorter in our study, might account for
these differences. With respect to anesthetic concentra-
tion, we found the greater biological effects at 3%
sevoflurane, similarly to other postconditioning studies
[39]. Interestingly, most of our results are also observed
at 7% sevoflurane, indicating that its dosage might differ-
entially affect cell types. For example, postconditioning
Figure 3 Effect of sevoflurane postconditioning on HUVEC cultures after LPS stimulation. (a) Effect on TLR2 expression; (b) effect on TLR4
expression; (c) levels of TNF-α and (d) IL-6 after sevoflurane postconditioning on LPS-treated HUVEC cultures. *p <0.05, ** p<0.01, *** p<0.001.
AFU: Arbitrary fluorescence units. Analysis was performed immediately after sevoflurane exposure (t=0), at 6 (t=6) and 24 (t=24) hours.
LPS: Lipopolysaccharide.
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in hippocampal tissue [30].
In vivo models of sepsis have demonstrated that pre-
treatment with sevoflurane decreased TNF-α and IL-6
[28]. Nevertheless, we are not aware of any previous
study reporting the postconditioning effect of sevoflu-
rane in endotoxaemia. Our results showing sevoflurane-
induced TLR2, TLR4 and cytokine decrease seem to
indicate that this protective effect may be also mediated
by anti-inflammatory mechanisms. Until what extent the
observed decrease of cytokine levels is due to TLR inhib-
ition is not explored in this preliminary study. Given the
important role of TLR on cytokine production via NF-ĸb
activation, it is possible that lower levels of TNF-α and IL-
6 might be, at least, partially explained by a decrease in
TLR expression. However, a direct causal effect between
TLR and cytokines cannot be concluded from our experi-
ments, but only to hypothesize about a possible biological
association that should be further explored.
Importantly, in agreement with previous studies
[40,41], TLR2 expression was low in our endothelial
cells, becoming higher after LPS stimulation. In this re-
gard, we cannot exclude the possibility that this activa-
tion might be, at least in part, due to the presence of
small amounts of lipoproteins in LPS preparation. Also
of note, an increase of TLR2 expression in endothelialcells under inflammatory conditions has also been dem-
onstrated, existing an important synergic effect between
LPS, TNF-α and TLR2 expression [42-44]. Due to this
complex scenario, we think that TLR2 levels should be
cautiously interpreted.
The ability of sevoflurane to modulate different im-
munity pathways and its potential role as an immuno-
modulatory drug in critically ill patients, expand its
therapeutic value beyond anesthetic properties. The
present study suggests that this volatile anesthetic
might help to preserve endothelium integrity in severe
endotoxaemia. Though caution should be exercised, it is
tempting to postulate that sevoflurane might offer a
therapeutic value in septic patients. In order to attenuate
inflammatory response and reduce organ failure,
targeting TLR signaling has been proposed as a thera-
peutic strategy in sepsis [35].
A minor limitation of this study is that, although
widely used as a model, stimulation of endothelial cells
with LPS does not completely replicate sepsis. In this
regard, future in vivo studies might help to clarify the
effect of sevoflurane postconditioning in sepsis. In
addition, because TLRs are major components of the in-
nate immune system, the potential effect of sevoflurane
on their expression should be also analyzed in other cell
types such as monocytes/macrophages or dendritic cells.
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Our results show that postconditioning with sevoflurane
using an experimental in vitro model of sepsis exerts
protective effects on cell viability, reducing TLR2 and
TLR4 expression as well as inflammatory markers in
human endothelial cells. More extensive in vitro and
in vivo studies exploring the ability of sevoflurane
postconditioning to modify immunity and inflammatory
pathways are required to elucidate its potential value in
the clinical setting.
Additional file
Additional file 1: Figure S1. Scheme showing experimental plan for
HUVEC cultures exposed to sevoflurane (a) and sevoflurane
postconditioning after LPS exposure (b). t=0: samples taken immediately
after exposure, t=6, t=24: samples taken 6 and 24 hours after exposure,
respectively. Figure S2. HUVEC stimulated with a concentration of 1 μg/
mL LPS showed a significant increase of TNF-alpha; and IL-6 levels in
culture media. Control: unstimulated cells; * p <0.05, ** p <0.001. Figure
S3. Exposure of HUVEC cultures to sevoflurane did not increase cell
death measured by MTT (a) or Trypan blue (b) assays at different
timepoints (all p≥0.05, n=9).
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